



Highlights

WG1: EUPancreas-SOP for pancreatic cancer biobanking launched.


WG1 produced this Standard Operating Procedure (SOP) to harmonize the pancreatic cancer tumour tissue biobanking process across Europe, so as to provide optimally preserved tissue for research. This SOP is available at www.eupancreas.com/wg1. WG1 has contributed to the standardizing of tumour tissue and epidemiological data collection, providing the tools needed to make the best possible research in pancreatic cancer.




 **WG1 & WG4: PancreOs (Pancreatic Cancer Overall Survival Registry).** The Spanish pilot study has been completed and the arrangements with other European pancreatic cancer registries initiatives are making progress. A kick-off meeting will be held in early March 2016 to seek the most suitable way of joining efforts to retrieve reliable pancreatic cancer survival data in Spain and in Europe (next phase). Various members of WG1 and WG4 EUPancreas members are giving support to this initiative.

 **WG2: Training School on Interactions in Complex Disease Analysis.** April 27-29, Antwerp (Belgium). Both the theory and application of methods to identify medically relevant interactions will be covered. Topics that will be addressed include statistical versus biological interactions, gene-environment interactions, causality, dynamical interaction systems, symbiotic and pathogenic interactions, protein networks and components-based path modeling. **Registration is now open at:** www.eupancreas.com/meetings-events

 **WG3: Training School on “Genomic Medicine”.** May 3-7, Portoroz (Slovenia). We will provide more information soon at: www.eupancreas.com/meetings-events


 **WG4: IV Annual EAPM Conference on personalized medicine.** April 5-7, Brussel (Belgium). This event will bring together stakeholder groups, healthcare professionals, academics, industry representatives, politicians and legislators, to discuss around the theme “Taking Stock: Where we are now and the necessary next steps to take to realize an environment for personalised medicine.”

 **World Cancer Day 2016.** February 4th. Our banner has been distributed through multiple dissemination channels.

 **10 new members** have joined EUPancreas. The EUPancreas platform joins over 200 European pancreatic cancer researchers.

 **Twitter:** @Pancreas has now 107 followers!

 **Grant calls** are being regularly posted at our website www.eupancreas.com



Early Career Investigators (ECIs):

 **Six new** Short-Term Scientific Missions (STSMs) were awarded in the **6th CALL FOR STSMs**. Awardees are published at www.eupancreas.com/training. The Action has awarded in total 22 STSMs!

Upcoming Scientific Events:


 **29 April 2016:** London Pancreas Workshop 2016. London, UK


 **9 to 12 June 2016:** International Symposium on Pancreatic Cancer 2016. Glasgow, UK

 **29 June to 2 July 2016:** ESMO World Congress on Gastrointestinal cancer. Barcelona, Spain


 **6 to 9 July 2016:** 48th meeting of the European Pancreatic Club. Liverpool, UK


The “COST Action BM1204 EUPancreas” has been acknowledged in:

 Malvezzi, et al. European cancer mortality predictions for the year 2016 with focus on leukemias. *Ann Oncol* 2016 Jan 26. [Epub ahead of print]

 Pineda, et al. Integration analysis of three omics data using penalized regression methods: an application to bladder cancer. *Plos Genet* 2015;11(12):e1005689

Some Pancreatic Cancer-related published studies:

 Fontana, et al. Development of a metabolites score for one-year mortality risk prediction in pancreatic adenocarcinoma patients. *Oncotarget* 2016 Feb 1. [Epub ahead of print].

 Illes, et a. New-onset type 2 diabetes mellitus – a high risk group suitable for the screening of pancreatic cancer? *Pancreatology* 2015 Dec 23. [Epub ahead of print]